摘要
目的研究子宫肌瘤治疗中米非司酮的临床应用价值及意义。方法回顾性剖析该院门诊在2015年6月—2017年2月间接诊的50例子宫肌瘤病患的病历资料,所有入选者都接受米非司酮药物治疗。对该组50例病患米非司酮治疗后相关激素水平的变化情况进行综合分析,并作出比较。结果经3~6个月的治疗之后,该组患者的总有效率达到96.0%;平均肌瘤体积缩小至(50.8±11.9)cm3、子宫体积缩小至(195.4±26.5)cm3、血红蛋白水升高至(93.5±10.4)g/L,均明显优于治疗前的(71.9±12.3)cm3、(303.6±31.3)cm3、(66.1±15.3)g/L,差异有统计学意义(P<0.05)。结论积极采取米非司酮药物治疗方案,对子宫肌瘤病患进行对症治疗,可促进其肌瘤体积缩小,提高血红蛋白水平,有效缓解临床症状,改善预后质量,值得临床借鉴。
Objective This paper tries to study the clinical value and significance of mifepristone in the treatment of uterine leiomyoma.Methods A retrospective analysis of 50 cases of uterine fibroids from June 2015 to February 2017 was conducted.All the subjects were treated with mifepristone.The changes of the related hormone levels in the 50 patients treated with mifepristone were analyzed and compared.Results After 3~6 months of treatment,the total effective rate of patients in this group was 96.0%.The average fibroid volume decreased to(50.8±11.9)cm3,uterus volume decreased to(195.4±26.5)cm3,hemoglobin water rise to(93.5±10.4)g/L,better than that before treatment of(71.9±12.3)cm3,(303.6±31.3)cm3,(66.1±15.3)g/L,the difference was statistically significant(P<0.05).Conclusion The active treatment of mifepristone in patients with uterine fibroids can be carried out by symptomatic treatment,which can promote the shrinkage of fibroids,improve the level of hemoglobin,relieve clinical symptoms and improve the quality of prognosis.It is worthy of clinical reference.
作者
党菲
DANG Fei(Department of Pharmacy,Obstetrics and Gynecology Hospital Affiliated to Capital Medical University,Beijing,100006 China)
出处
《中外医疗》
2018年第1期144-145,198,共3页
China & Foreign Medical Treatment
关键词
子宫肌瘤
血红蛋白
米非司酮
应用价值
Uterine fibroids
Hematocrystallin
Mifepristone
Application value
